Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.

Slides:

Advertisements

Similar presentations

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Advertisements

Volume 155, Issue 3, Pages (March 1996)

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.

Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Short-pulse B–non-Hodgkin lymphoma–type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Nat. Rev. Urol. doi: /nrurol

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.

by Alexander Röth, Andreas Hüttmann, Russell P

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

The Effects of Interleukin 10 and Interferon γ Cytokine Gene Polymorphisms on Survival after Autologous Bone Marrow Transplantation for Patients with.

Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation Mary J. Ninan, Christopher.

Chronic graft-versus-host disease

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

Nat. Rev. Urol. doi: /nrurol

Costs and Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Children Are Predictable Susanne Matthes-Martin, Ulrike Pötschger, Ronald Barr,

Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

A Low Incidence of Nontuberculous Mycobacterial Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients Elif Unal, Catherine Yen,

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Comparable Long-Term Survival after Bone Marrow versus Peripheral Blood Progenitor Cell Transplantation from Matched Unrelated Donors in Children with.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

Volume 24, Issue 9, Pages (September 2016)

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Survival in patients with colorectal cancer diagnosed by screening colonoscopy Kilian Friedrich, MD, Ludwig Grüter, MD, Daniel Gotthardt, MD, PhD, Christoph.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

by Lapo Alinari, and Kristie A. Blum

Once Daily i. v. Busulfan and Fludarabine (i. v

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90 by Alfred Reiter, Martin Schrappe, Markus Tiemann, Wolf-Dieter Ludwig, Elif Yakisan, Martin Zimmermann, Georg Mann, Andreas Chott, Wolfram Ebell, Thomas Klingebiel, Norbert Graf, Bernhard Kremens, Stefan Müller-Weihrich, Hans-Jürgen Plüss, Felix Zintl, Günter Henze, and Hansjörg Riehm Blood Volume 94(10):3294-3306 November 15, 1999 ©1999 by American Society of Hematology

Treatment strategy. Treatment strategy. Patients were stratified into 3 risk groups: R1, R2, and R3. The composition of therapy courses is given in Table 1. V, cytoreductive prophase; CR, complete response; SL-OP, second-look operation; ABMT, autologous BMT or blood stem cell transplantation. Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Distribution of pretreatment serum LDH concentrations (logarithmic scale) according to stage of disease. Distribution of pretreatment serum LDH concentrations (logarithmic scale) according to stage of disease. (○) Patients surviving event-free; (□) toxic death; (▴) patients suffering from progress; (*) patients who developed second malignancy. From 16 patyients (2, 7, 2, 1, and 4 of stage I, II, III, IV, and B-ALL, respectively) the LDH values are lacking. One of these patients (stage IV) relapsed, and 2 B-ALL patients died of acute cell lysis syndrome. One patient (stage III) with LDH less than 100 U/L and 3 patients (B-ALL) with LDH greater than 10,000 are not depicted; 1 of them (B-ALL) died of acute cell lysis syndrome. Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Kaplan-Meier estimate of EFS according to stage. Kaplan-Meier estimate of EFS according to stage. SE, standard error. Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology

Kaplan-Meier estimate of EFS for patients with abdominal stage III B-NHL and LDH ≥500 U/L in trial NHL-BFM 90 and in the preceding trial NHL-BFM 86. Kaplan-Meier estimate of EFS for patients with abdominal stage III B-NHL and LDH ≥500 U/L in trial NHL-BFM 90 and in the preceding trial NHL-BFM 86. SE, standard error. Alfred Reiter et al. Blood 1999;94:3294-3306 ©1999 by American Society of Hematology